ACHV Achieve Life Sciences, Inc.
USHealthcareAs of 2026-07-10 13:39
Why ACHV matters now
Achieve Life Sciences, Inc. (ACHV) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.09 with -4.92% on the session and $624.7M in market capitalization; recent performance reads 1-month +8.99% and YTD -2.41%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.2M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.1%.
The latest indexable market news headline is "Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting" from MarketBeat.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.00; recent insider activity includes Farrow Jeffrey S filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
24.25
P/S
0.00
EV/EBITDA
-9.53
DCF Value
$0.12
FCF Yield
-9.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-193.5%
ROA
-157.0%
ROIC
-195.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.2M | $-0.19 |
| Q4 2025 | $0.00 | $-14.7M | $-0.28 |
| FY 2025 | $0.00 | $-54.6M | $-1.25 |
| Q3 2025 | $0.00 | $-14.4M | $-0.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.00
Target (Median)
$13.00
Target Range
$13.00 - $13.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
2.26
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.